Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus radiotherapy after TURBT for bladder-preserving treatment of muscle-invasive bladder cancer
ChiCTR1900026627Phase 4Not yet recruiting
- Sponsor
- Liuzhou Traditional Chinese Medicine Hospital
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in bladder cancer and muscle-invasive bladder cancer (MIBC), sponsored by Liuzhou Traditional Chinese Medicine Hospital. Primary endpoint: Tumor size. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on ChiCTR1900026627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026627.